Assessing the Impact of Control-IQ Technology on Quality of Life and Glycemic Control in Children and Youth With Type 1 Diabetes in a Canadian Context
Status: Completed
Location: See location...
Study Type: Observational
SUMMARY
Objective: To determine pediatric T1D patients' and their parents' perceptions of the impact of Control-IQ on their psychosocial functioning and quality of life.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 6
Maximum Age: 18
Healthy Volunteers: f
View:
• Diagnosis of T1D
• Age 6-18 years
• Currently using the Tandem t:slim X2 insulin pump with Dexcom G6 CGM, who are initiating Control-IQ
Locations
Other Locations
Canada
Children's Hospital of Eastern Ontario
Ottawa
Time Frame
Start Date: 2021-03-15
Completion Date: 2021-10-26
Participants
Target number of participants: 65
Authors
Related Therapeutic Areas
Sponsors
Leads: Children's Hospital of Eastern Ontario
Collaborators: Tandem Diabetes Care, Inc.